An audit of the HIV drug resistance testing program in Malawi
Malawi Medical Journal · 2025
DOI: 10.4314/mmj.v37i1.3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Malawi Medical Journal, 2025. Verfasst von Hope Kanise und 14 weiteren Autor:innen. Beteiligte Einrichtung: Partners in Hope, Lilongwe, Malawi. Hauptthemen laut MEDLINE: HIV Infections, Drug Resistance, Viral, Heterocyclic Compounds, 3-Ring, HIV-1. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Fogarty International Center of the National Institutes of Health.
Abstract (Originalsprache)
IntroductionFor persons failing on dolutegravir- and protease inhibitor-based antiretroviral therapy (ART) regimens, Malawi’s HIV program requires confirmation of HIV drug resistance (HIVDR) before switching to next-line regimens. Approval of applications for HIVDR testing is determined by a national HIVDR committee that also provides management recommendations based on HIVDR test results. We audited HIVDR test applications for all ages in Malawi’s national ART program to evaluate the HIVDR testing process and explore short-term outcomes, including viral suppression.MethodsWe conducted a retrospective review of routinely collected data from applications for HIVDR testing registered between July 2020 and December 2021. We determined drop-offs at steps of the HIVDR testing cascade: approval for genotyping, sample collection, receiving results, completion of genotypic sequencing, provision of management recommendations and implementation of recommendations. We assessed ART outcomes, including the first viral load (VL) result ≥6 months after recommendations from the HIVDR committee.Results228 HIVDR applications were received, of which 75% (172/228) were approved. Of these, 72% (124/172) had samples sent to laboratory and 122 genotyping results were obtained. 75% (92/122) of samples were successfully sequenced and 68% (65/92) sequences had ≥1 major drug resistance-associated mutation, including 17% with moderate or high-level dolutegravir resistance of individuals on dolutegravir-based regimens. Treatment outcomes were available for 90 clients: 65 were alive on ART, 3 had defaulted, 12 died, 9 transferred out and 1 stopped ART. Of 68 available follow-up VL results, 34 (51%) were
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Partners in Hope, Lilongwe, Malawi.
- The Lighthouse Trust, Lilongwe, Malawi.
- Department of HIV, AIDS, STIs and Viral hepatitis, Ministry of Health, Lilongwe, Malawi.
- Baylor College of Medicine Children's Foundation-Malawi, Lilongwe, Malawi.
- Baylor College of Medicine, Houston, USA.
- University of North Carolina Project Malawi, Lilongwe, Malawi.
Förderung
- Fogarty International Center of the National Institutes of Health
Zitieren
APA
Kanise, H., Nyirenda, K., Bisani, P., Matola, B. W., Makwaya, A., Simon, K., Cox, C., Hosseinipour, M. C., Kanyama, C., Worku, A., Phiri, S., Hoffman, R. M., Nyirenda, R., Heller, T., & van Oosterhout, J. J. (2025). An audit of the HIV drug resistance testing program in Malawi. Malawi Medical Journal. https://doi.org/10.4314/mmj.v37i1.3
Vancouver
Kanise H, Nyirenda K, Bisani P, Matola BW, Makwaya A, Simon K, et al. An audit of the HIV drug resistance testing program in Malawi. Malawi Medical Journal. 2025. doi:10.4314/mmj.v37i1.3
BibTeX
@article{Kanise2025,
author = {Kanise, Hope and Nyirenda, Khumbo and Bisani, Pachawo and Matola, Bilaal W and Makwaya, Amos and Simon, Katherine and Cox, Carrie and Hosseinipour, Mina C and Kanyama, Cecilia and Worku, Anteneh and Phiri, Sam and Hoffman, Risa M and Nyirenda, Rose and Heller, Tom and van Oosterhout, Joep J},
title = {An audit of the HIV drug resistance testing program in Malawi},
journal = {Malawi Medical Journal},
year = {2025},
doi = {10.4314/mmj.v37i1.3}
}
EUVIMED